Treatment Switching in Virologically Suppressed HIV Patients
Key Takeaways from the Interview wiht Dr.Gandhi on HIV Treatment Switching:
Here’s a breakdown of the vital points from the interview, categorized for clarity:
1. Doravirine/Islatravir – A New Option:
* Novel Mechanism: Doravirine is an established NNRTI, while islatravir is a first-in-class nucleoside reverse transcriptase translocation inhibitor.
* Non-Inferiority: Early studies show it’s as effective as standard 3-drug regimens for virologically suppressed patients.
* Benefits: Possibly helpful for patients experiencing side effects from integrase inhibitors (sleep issues, brain fog, weight gain). Favorable AE profile and minimal drug-drug interactions.
* Limitations: Doesn’t provide coverage for Hepatitis B virus (HBV).
* Future Data: Awaiting head-to-head comparison data with bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve patients.
2. HBV Coinfection & Treatment Switches:
* Prevalence: 5-10% of US HIV patients also have HBV, higher rates in endemic regions.
* Management:
* With Chronic HBV: Requires separate HBV treatment (tenofovir or entecavir) alongside the 2-drug HIV regimen.
* Without Chronic HBV: Confirm immunity to HBV before stopping tenofovir-containing regimens. Regular monitoring is crucial.
3.Other Considerations for Switching:
* Cardiovascular Disease: prioritize lipid-neutral regimens. Avoid protease inhibitors due to cholesterol effects. Early statin use is recommended (based on REPRIEVE trial results – 35% reduction in cardiovascular events if 10-year risk > 5%).
* Drug-Drug Interactions: Be vigilant!
* Dolutegravir can increase metformin levels (limit to 1000mg daily).
* Integrase inhibitor absorption can be reduced by multivalent cations (calcium,iron,magnesium,aluminum,zinc) – space these supplements/medications 6 hours apart from HIV meds.
4. gaps in Guidelines & Addressing Them:
* Weight Gain: A significant issue. some weight gain is a positive sign of returning to health, but excessive gain linked to ARTs is a concern.
* Switching regimens doesn’t usually reverse weight gain.
* Focus on lifestyle interventions (diet, exercise).
* GLP-1 receptor agonists may be considered for diabetes/obesity,but off-label use is discouraged.
* Negotiating Gaps: Emphasize monitoring, lifestyle support, and individualized patient care.
5. Comorbidity prevention & Management:
* Cardiovascular Risk Reduction: Switch off abacavir (linked to MI) and protease inhibitors (lipid effects). Early statin use.
In essence, Dr. Gandhi emphasizes a personalized approach to treatment switching, considering not just viral suppression but also the patient’s overall health, potential side effects, drug interactions, and comorbidities. The emergence of new regimens like doravirine/islatravir offers more options, but careful assessment and management are crucial for optimal outcomes.